Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Enjaymo“
Suchtreffer
Begriffe & Kennungen
Enjaymo
Eintrag öffnenEnjaymo · 4.1 Therapeutic indications · 1
Eintrag öffnenEnjaymo · 4.3 Contraindications · 1
Eintrag öffnenEnjaymo · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenEnjaymo · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenEnjaymo · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenEnjaymo · 4.5 · No interaction studies have been performed. Enjaymo is an unlikely candidate for cytochrome P450 mediated drug
Eintrag öffnenEnjaymo · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenEnjaymo · 4.8 Undesirable effects · 1
Eintrag öffnenEnjaymo · 4.8 · 6 Table 2 List of adverse reactions in CADENZA and CARDINAL studies
Eintrag öffnenEnjaymo · 4.8 · 7 Immunogenicity
Eintrag öffnenEnjaymo · 4.8 · Immunogenicity of sutimlimab was assessed in CAD patients in the CARDINAL and CADENZA studies at baseline, dur
Eintrag öffnenEnjaymo · 4.8 · Listed in Table 2 are adverse reactions observed in the CADENZA and CARDINAL studies presented by system organ
Eintrag öffnenEnjaymo · 4.8 · MedDRA System Organ Class Very common Common Infections and infestations Urinary tract infection Lower respira
Eintrag öffnenEnjaymo · 4.8 · Of the 66 patients who participated in CADENZA and CARDINAL studies, serious infections were reported in 10 (1
Eintrag öffnenEnjaymo · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnenEnjaymo · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
Eintrag öffnenEnjaymo · 4.8 · Serious infections
Eintrag öffnenEnjaymo · 4.8 · Summary of safety profile
Eintrag öffnenEnjaymo · 4.8 · Tabulated list of adverse reactions
Eintrag öffnen